A major challenge in RNA-targeted drug discovery is determining where small

molecules bind on RNA, what structures they recognize, and whether those binding

events translate into functional outcomes. As structural, probing, and biophysical tools

advance, the field still lacks standardized approaches for connecting RNA structure,

binding-site identification, and compound optimization.

Join medicinal chemists, structural biologists, RNA biologists, and teams improving

structure-guided design to explore practical strategies for:

• Predicting RNA ligandability by identifying structures that can support selective small-molecule binding
• Prioritizing tractable RNA targets by linking function, binding pockets and confidence in on-target engagement
• Evaluating biophysical and structural methods to measure RNA ligand recognition, affinity and conformational change